



# AIVLOSIN<sup>®</sup>

(62.5% w/w Tylvalosin as Tylvalosin Tartrate)  
**Water Soluble Granules**



## Aivlosin<sup>®</sup> WSG fights multiple diseases effectively and efficiently

Aivlosin administration at **50 ppm** in drinking water for **five consecutive days** is highly effective against ileitis (PPE), swine respiratory disease (SRD) and *Mycoplasma hyopneumoniae* (*M. hyo*).

### Ileitis

Reduced severity of PPE clinical signs, gross lesions, and pathogen shedding


Compared to challenged, non-medicated controls, Aivlosin significantly reduced the severity of clinical signs of PPE ( $P < 0.001$ ). Aivlosin significantly reduced the severity of gross intestinal PPE lesions ( $P = 0.0103$ ), and significantly decreased the frequency of positive PCR and IHC samples ( $P < 0.02$ ).<sup>1,2</sup>

# 24.2%


improved feed efficiency

Feed:gain ratio improved 24.2% in pigs medicated with Aivlosin compared to challenged, non-medicated control pigs ( $P < 0.0001$ ).<sup>1,2</sup>

ADG (KG/DAY)



FEED/GAIN



# 54.8%

improved ADG


ADG improved 54.8% in pigs medicated with Aivlosin compared to challenged, non-medicated control pigs ( $P = 0.0051$ ).<sup>1,2</sup>

# 0%

mortality

14.9% of challenged non-medicated control pigs died, but no PPE mortality occurred in Aivlosin-treated pigs ( $P < 0.001$ ).<sup>1,2</sup>

MORTALITY (%)




## Mycoplasma hyopneumoniae

# 50%

fewer lung lesion scores

The estimated mean lung lesion scores were 5.1% for the Aivlosin-treated group and 10.9% for the challenged, non-treated control group, ( $P < 0.0001$ ).<sup>3</sup>

## Compatibility



Not Compatible

Aivlosin poses no known toxicity concerns or elevated risk of adverse interactions when used according to label directions in swine fed rations containing Skycis® (or Posistac® in Canada).

## Swine respiratory disease

FEED EFFICIENCY

# 0.18

 better

Pen feed efficiency (pounds of feed per pounds of gain) was 1.49 in Aivlosin WSG pigs compared to 1.67 in natural challenged, non-treated control pigs ( $P < 0.05$ ).<sup>4</sup>

# 17%

lower lung lesion scores and reduced severity of clinical signs

Pen mean lung lesion scores were 12.95% in Aivlosin WSG pigs compared to 15.65% in natural challenged non-treated control pigs ( $P < 0.05$ ).<sup>3</sup> Aivlosin significantly reduced the severity of clinical signs of SRD compared to non-medicated controls ( $P < 0.05$ ).<sup>4</sup>

ADG **0.15** lbs/day higher

Pen ADG in pounds per pig per day was 1.01 in Aivlosin WSG pigs compared to 0.86 in natural challenged, non-treated controls ( $P < 0.05$ ).<sup>4</sup>

# 40%

 reduced mortality

Mortality percentage was 3.9% in Aivlosin WSG pigs and 6.5% in natural challenged, non-treated control pigs, statistical analysis was not applicable for this variable due to low counts.<sup>4</sup>

1. ECO Animal Health study EFF.US.070142, data on file.  
2. ECO Animal Health study EFF.US.090-170, data on file.  
3. ECO Animal Health study EFF.US.180616, data on file.  
4. ECO Animal Health study EFF.US.130298, data on file.

